RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that ...

Adding the glucagon-like peptide 1 receptor agonist (GLP-1 RA) liraglutide to standard therapy reduces the risk for recurrent stroke in patients with type 2 diabetes (T2D) and a minor acute ...

Please provide your email address to receive an email when new articles are posted on . Liraglutide may improve outcomes and prognosis after minor stroke/transient ischemic attack in patients with ...

Hims plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide and tirzepatide. Despite the setback, Hims shows strong financial health with 77% Y ...

Bengaluru: Biocon Limited, an innovation-led global biopharmaceutical company, has announced the launch of its GLP-1 peptide, ...

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...